Recurrent glioblastoma

Researchers are testing CHANK-101, a therapy made from a patient's own natural killer (NK) cells, in adults with glioblastoma that has returned after standard treatment. The study enrolls 60 participants who receive intravenous infusions of these cells every two weeks for up to 1…

This phase 1 trial tests whether FPS-ZM1, a drug that blocks an inflammation pathway, can safely control brain swelling that often occurs after surgery for glioblastoma, a type of brain cancer. Researchers will give FPS-ZM1 with or without the steroid dexamethasone to about 24 ad…

This early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main…

This early-phase trial tests a new way to treat recurrent glioblastoma, an aggressive brain cancer. Tiny radioactive beads called SIR-Spheres® are injected into the blood vessels feeding the tumour to deliver radiation directly inside it. The study aims to see if this approach is…

This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 par…